Faculty profile

John Stagg

Back to faculty

ProfessorGoodman Cancer Institute, Microbiology and ImmunologyMcGill University

John Stagg

Professor

Goodman Cancer Institute, Microbiology and Immunology

Faculty of Medicine and Health Sciences

McGill University

Montreal, Quebec, Canada

Supervision signals

Professors usually supervise graduate students in their department's programs.
159 publications in the last five years, latest in 2026.
Senior (last) author on 53 recent papers, a sign of leading a research group.
Principal investigator on 9 research grants (6 CIHR, 2 CFI, 1 FRQS), most recently in 2026.

These signals come from public records, including federal and provincial funding decisions. Ask the professor or the graduate program whether they are taking new students.

Academic metrics

385

Publications

20,685

Citations

271

Collaborators

Grants

Publications by year

Counts cover the publications linked to this profile. Citations and the h-index appear when the source records them.

Roles and appointments

Department of Microbiology and Immunology Director, Rosalind and Morris Goodman Cancer Institute

Profiles and links

University Profile

Search on Google Scholar

Search on ResearchGate

iDORCID OpenAlex

Find them onX · LinkedIn · Bluesky · YouTube

Signals and details

Research

Read how they describe their research on their McGill University profile.

Immunologie du cancer du sein, cancer de l’ovaire et cancer de la prostate.

Latest papers

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.
Nature medicine · 2026
The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer.
Oncogene · 2026
Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+/HER2- breast cancer: a randomised phase 2 trial
Figshare · 2026

All 385 publications

Latest funding

Discovery of mechanisms of cancer immune evasion and next-generation immunotherapies
CFI · 2026 · Principal investigator
$560,825
Harnessing Humoral Immunity and Bacterial Loss for the Development of a Live Biotherapeutic Product to Improve Microbiome and Immunotherapy Response in Lung Cancer
CIHR · 2025 · Co-investigator
$918,000
Deciphering the role of protease-activated receptor 2 in immuno-oncology
CIHR · 2023 · Nominated PI
$1,013,625

All 12 grants and awards

From the 150 most recent of 385 publications.

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.

De Caluwé A, Desmoulins I, Cao K, Remouchamps V, Baten A, Longton E, Peignaux K, Joaquin Garcia A, Venet D, Arecco L, Agostinetto E, Nader-Marta G, Denis Z, Dhont J, Kristanto P, Catteau X, Larsimont D, Salgado R, Poortmans P, Stagg J, Sotiriou C, Piccart M, Ignatiadis M, Romano E, Buisseret L

Nature medicine20264 citationsOpen Access

DOI: 10.1038/s41591-026-04453-z PMID: 42350643

The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer.

Acevedo M, Dô F, El-Mortada F, Tanguay PL, Voisin L, Houles T, Lavoie G, Allard D, Roux PP, Stagg J, Doré S, Walsh L, Fourtounis J, Bonneil E, Meloche S, Servant MJ

Oncogene20262 citations

DOI: 10.1038/s41388-026-03695-y PMID: 41714442

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+/HER2- breast cancer: a randomised phase 2 trial

Alex De Caluwé, Isabelle Desmoulins, Kim Cao, Vincent Remouchamps, Adinda Baten, E. Longton, Karine Peignaux, Andrea Joaquin Garcia, Luca Arecco, Elisa Agostinetto, Guilherme Nader-Marta, Zoë Denis, Jennifer Dhont, Paulus Kristanto, Xavier Catteau, Denis Larsimont, Roberto Salgado, Philip Poortmans, J. C. A. Stagg, Christos Sotiriou, Martine Piccart, Michail Ignatiadis, Emanuela Romano, Laurence Buisseret, David Venet

Figshare20261 citationsOpen Access

DOI: 10.6084/m9.figshare.29489597

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.

Aouad S, Kadiri M, Allard D, Skora E, Giraud L, Fuselier C, Desroys du Roure P, Mousson A, Janvier A, Baron L, Franchet C, Lecru L, Routy B, Malo J, Brugat T, Blayo AL, Schann S, Stagg J

Journal for immunotherapy of cancer20261 citationsSenior authorOpen Access

DOI: 10.1136/jitc-2025-013507 PMID: 41932811

PRMT7 restricts CD8 + T cells expansion via the NF-κB pathway

Nivine Srour, Kaixiu Luo, David J. Allard, Yan Xiong, Zhenbao Yu, Theodore Papadopoulos, François Santinon, Cheng-Hsun Hsieh, J. C. A. Stagg, Dalia Barsyte-Lovejoy, Sonia Victoria Del Rincon, Jian Jin, Stéphane Richard

bioRxiv (Cold Spring Harbor Laboratory)2026Open Access

DOI: 10.64898/2026.04.25.720790

PRMT7 restricts CD8+ T cells expansion via the NF-ΚB pathway

Nivine Srour, Kaixiu Luo, David Allard, Yan Xiong, Zhenbao Yu, Theodore Papadopoulos, François Santinon, Cheng-Hsun Hsieh, Anthony Parent, John Stagg, Simon Turcotte, Dalia Baršytė-Lovejoy, Stéphanie Lehoux, Sonia V. del Rincon, Jian Jun Jin, Stéphane Richard

Nature Communications2026Open Access

DOI: 10.1038/s41467-026-77155-2

Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.

Catteau X, Noël JC, Fallas J, Charry M, Denis Z, De Caluwé A, Stagg J, Sotiriou C, Buisseret L

Discover oncology2026Open Access

DOI: 10.1007/s12672-026-04959-5 PMID: 42010032

Spatial immune profiling to identify GPNMB as a mediator of immune suppression that limits response to PD-1 blockade in TNBC.

Anna-Maria Lazaratos, Matthew G. Annis, Ying Liu, Elham Karimi, Yunyun Shen, Afnan Abu-Thuraia, John Heath, Emilie Solymoss, Dongmei Zuo, Vanessa Brien, Hellen Kuasne, Marco Biondini, Matthew Dankner, Yuhong Wei, April A. N. Rose, Josie Ursini‐Siegel, J. C. A. Stagg, Morag Park, Logan Walsh, Peter Siegel

Journal of Clinical Oncology2026

DOI: 10.1200/jco.2026.44.16_suppl.2582

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+/HER2- breast cancer: a randomised phase 2 trial

Figshare2026Open Access

DOI: 10.6084/m9.figshare.29489597.v1

Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis.

Allard D, Cormery J, Bricha S, Fuselier C, Abbas Aghababazadeh F, Giraud L, Skora E, Haibe-Kains B, Stagg J

Cancer research202522 citationsSenior author

DOI: 10.1158/0008-5472.can-24-1875 PMID: 39652568

Discovery of mechanisms of cancer immune evasion and next-generation immunotherapies

Principal investigatorCFI2026John R. Evans Leaders Fund: John R. Evans Leaders Fund – Funding for research infrastructure

Principal investigators: Stagg, John

Keywords: immunotherapy, immune checkpoint, biotherapeutics, hypoxia hypoxia cell culture suite, live-cell imaging platform, molecular biology analys

$560,825

Harnessing Humoral Immunity and Bacterial Loss for the Development of a Live Biotherapeutic Product to Improve Microbiome and Immunotherapy Response in Lung Cancer

Co-investigatorCIHR2025Project Grant

Principal investigators: Routy, Bertrand

Keywords: Fecal Microbiota Transplantation; Immune Checkpoint Inhibitors; Microbiome

$918,000

Deciphering the role of protease-activated receptor 2 in immuno-oncology

Nominated PICIHR2023Project Grant

Principal investigators: Stagg, John

Keywords: Immunotherapy

$1,013,625

Chercheurs-boursiers

Principal investigatorFRQS2022Chercheurs-boursiers

Principal investigators: Stagg, John

Keywords: IMMUNO-ONCOLOGIE, IMMUNE CHECKPOINT, ADENOSINE, CD73, CD39, IMMUNOTHERAPIE; Cancer; Immunothérapie; Cancer de l'appareil digestif

$100,545

Targeting the extracellular adenosine pathway in pancreatic and liver cancers

Nominated PICIHR2021Project Grant

Principal investigators: Stagg, John

Keywords: Adenosine; Immune Checkpoint; Immunotherapy; Pancreatic Cancer

$765,000

T-cells and Cancer Immunotherapy

Co-investigatorCFI2020Innovation Fund: Innovation Fund 2020

Principal investigators: Nathalie Labrecque, Christopher Rudd

Keywords: Research to improve immunotherapy based on our expertise on the identification and function of T-cell receptors and signalling pathways. Cytometry, microscopes, PCR, workstations, live cell imaging, IVIS, sequencing

$3,976,787

Immune-stimulatory antibody-drug conjugates for treatment of breast cancer

Nominated PICIHR2018Operating Grant: CCS Innovation Grants

Principal investigators: Stagg, John

Keywords: Immune-Stimulatory Antibody-Drug Conjugates

$66,000

Targeting the CD73-adenosine pathway in cancer

Nominated PICIHR2016Project Grant

Principal investigators: Stagg, John

Keywords: Antibody Therapy; Breast Cancer; Her2; Immune Checkpoint; Immunotherapy; Pd-1; Targeted Therapy

$1,162,040

Injectable thermosensitive hydrogel as delivery vehicle of lymphocytes for cancer immunotherapy

Co-investigatorCIHR2015Proof of Principle Program - Phase I

Principal investigators: Lerouge, Sophie; Lapointe, Réjean

Keywords: Adoptive Cell Therapy (Act); Animal Model; Cancer; Cell Delivery; Chitosan; Hydrogel; Immunotherapy; Melanoma; Thermosensitive; Tumor-Infiltrating Lymphocytes

$141,000

Remodeling of the tumor microenvironment by CD73: a therapeutic target

Nominated PICIHR2014CIHR New Investigator

Principal investigators: Stagg, John

Keywords: Cancer Immunotherapy

$300,000

From public funding decisions: CIHR since 2008, NSERC since 1991 and SSHRC since 1998 with their latest competition results, the Canada Foundation for Innovation, Genome Canada, the Canadian Space Agency, Canada Research Chairs, the Fonds de recherche du Québec, Ontario research funding, Michael Smith Health Research BC, the Canadian Cancer Society, Heart & Stroke and Brain Canada.

Profile data last refreshed on September 29, 2026 from the university directory, publication records and public research funding records.

Something wrong or missing on this profile? Suggest a correction

John Stagg

Research

Latest papers

Latest funding

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+HER2- breast cancer: a randomized phase 2 trial.

The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver &#x3b2;-catenin in colorectal cancer.

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+/HER2- breast cancer: a randomised phase 2 trial

Targeting PAR-2 with a negative allosteric modulator increases tumor antigen presentation and potentiates anti-PD-1 immunotherapy.

PRMT7 restricts CD8 + T cells expansion via the NF-κB pathway

PRMT7 restricts CD8+ T cells expansion via the NF-ΚB pathway

Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.

Spatial immune profiling to identify GPNMB as a mediator of immune suppression that limits response to PD-1 blockade in TNBC.

Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ER+/HER2- breast cancer: a randomised phase 2 trial

Adenosine Uptake through the Nucleoside Transporter ENT1 Suppresses Antitumor Immunity and T-cell Pyrimidine Synthesis.

Discovery of mechanisms of cancer immune evasion and next-generation immunotherapies

Harnessing Humoral Immunity and Bacterial Loss for the Development of a Live Biotherapeutic Product to Improve Microbiome and Immunotherapy Response in Lung Cancer

Deciphering the role of protease-activated receptor 2 in immuno-oncology

Chercheurs-boursiers

Targeting the extracellular adenosine pathway in pancreatic and liver cancers

T-cells and Cancer Immunotherapy

Immune-stimulatory antibody-drug conjugates for treatment of breast cancer

Targeting the CD73-adenosine pathway in cancer

Injectable thermosensitive hydrogel as delivery vehicle of lymphocytes for cancer immunotherapy

Remodeling of the tumor microenvironment by CD73: a therapeutic target

Frequent collaborators

Benjamin Haibe-Kains

Anne-Marie Mes-Masson

Réjean Lapointe

Sarkis Meterissian

Catalin Mihalcioiu

Bertrand Routy

Kevin Petrecca

Simon Turcotte

Philippe Bedard

Wilson Miller

Sonia Del Rincon

Hamed Najafabadi

Ari Meguerditchian

Luc Baron

Jean-François Cailhier

Hamed Shateri Najafabadi

Dominique Trudel

Daniela Quail

Kathleen McCoy

Morag Park

ATILLA Omeroglu

Pierre-Olivier Gaudreau

Matthew Cheung

John Waldron

Dale Brown

Jim Woodgett

Ming Tsao

Ebba Kurz

Normand Blais

Mustapha Tehfe

Jean Chalaoui

Charles Leduc

Philippe Stephenson

Saima Hassan

Pierre Fiset

Elizabeth Arslanian

The deubiquitinase USP17 regulates the expression and activity of the oncogenic driver β-catenin in colorectal cancer.